Vifor (international) Ag

Chdi Foundation, Inc.

Haplogen Gmbh

Other

Dac Slr

Congenia S.r.l.

Christopher John Yarnold

Stephen Martin Courtney

Wilm Buhr

Susanna Burckhardt

Franz Dürrenberger

Jon Shepherd

Susan Boyce

Celia Dominguez

John Wityak

Cristina Lecci

Stefan Reim

Michael Burgert

John Scott

Aris Kalogerakis

Paula Pena

Richard Jarjes-Pike

Vania Manolova

Leticia M Toledo-Sherman

Paula C De Aguiar Pena

Dirk Winkler

Andreas Scheel

Mark Whittaker

Patricia Leonie Amouzegh

Mark Anthony Kerry

Wolfgang Fischl

Frederick Arthur Brookfield

Christopher McGuigan

Jan Balzarini

Michael Edward Prime

Peter Geisser

Erik De Clercq

Saverio Minucci

Felix Funk

Paolo Bernardi

Richard Waldron Marston

Gilles Pain

Peter Neville Ingram

Douglas Macdonald

Inaki Morao

Joachim Kraemer

Marco Giorgio

PierGiuseppe Pellicci

Mihaly Daniel Gardiner

Thomas Hesterkamp

Christian Aldo Georges Napoleon Montalbetti

Oliver Robin Barker

Garry Jones

Ewa Iwona Chudyk

Owen Clifford Mather

Albertus A Ellenbroek

Mark P Ridgill

Mark Slack

Tara Davenport

Graham Dawson

Vincent A Corden

Kevin Thewlis

Jean-Francois Pons

Paula Cristina De Aguiar Pena

Cella Dominguez

The present invention relates to novel compounds of general formula (I) wherein Rto Rand n have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or ameliorating viral infections and their use for treating, preventing or ameliorating diseases which are associated with PLA2G16. 

Antiviral compounds

The present invention relates to novel compounds of general formula (I) wherein the groups X, and Rto Rhave the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or ameliorating viral infections and their use for treating, preventing or ameliorating diseases which are associated with PLA2G16. 

The invention relates to novel compounds of the general formula (I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.

Ferroportin inhibitors

The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis. 

The invention relates to novel compounds of the general formula (A-I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula (AA) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis. 

Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof

The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.

Sulfonaminoquinoline hepcidin antagonists

Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.

Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof

Compounds of general formula (I); or a stereoisomers, tautomers, pharmaceutically acceptable salts, or prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R8 and R9 are as defined herein, are useful for the treatment of diseases and conditions which are mediated by excessive or inappropriate Hsp90 activity such as cancers, viral infection and inflammatory diseases or conditions. 

Quinazolin-oxime derivatives as Hsp90 inhibitors

The invention discloses the use of a compound of formula (I), wherein R, R, R, and Reach independently represents: hydrogen; halo; hydroxy; (C-C) alkyl optionally substituted by hydroxy or (C-C) alkoxy; (C-C) haloalkyl; (C-C) alkoxy; and (C-C) haloalkoxy; for the preparation of a medicament for the prevention and/or treatment of diseases resulting from opening of the MPTP which are characterized by degenerative tissue damages, in particular, diabetes and diabetic complications, neurological diseases and stroke, heart infarction, inherited dystrophies and hepatitis, more particularly, diabetic vascular diseases, such as diabetic retinopathy, and neurodegenerative disorders, such as multiple sclerosis. Further objects are a group of selected individual compounds of formula (I) for use as medicaments and a further group of selected individual compounds of formula (I) as novel compounds. 

Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting MPT

A compound having formula (I), wherein R is selected from the group comprising C to C alkyl, C to C cycloalkyl, halogens, aryl and alkylaryl; R&prime; is selected from the group comprising hydrogen, alkyl, cycloalkyl, halogens, amino, alkylamino, dialkylamino, nitro, cyano, alkyoxy, aryloxy, thiol, alkylthiol, arythiol, alkyl; R&Prime; is selected from the group comprising hydrogen, alkyl, cycloalkyl, halogens, alkyloxy, aryloxy and aryl; Q is selected from the group comprising O, S and CY , where Y may be the same or different and is selected from H, alkyl and halogens; X is selected from the group comprising O, NH, S, N-alkyl, (CH ) where n is 1 to 10, and CY where Y may be the same or different and is selected from hydrogen, alkyl and halogens; Z is selected from the group comprising O, S, NH, and N alkyl; U&Prime; is H and U&prime; is selected from H and CH T, or U&prime; and U&Prime; are joined so as to form a ring moiety including Q wherein U&prime;-U&Prime; together is respectively selected from the group comprising &mdash;CTH&mdash;CT&prime;T&Prime;&mdash; and &mdash;CT&boxH;CT&mdash; and &mdash;CT&prime;&boxH;CT&prime;&mdash;, so as to provide ring moieties selected from the group comprising formula (II) and (III) wherein T is selected from the group comprising OH, H, halogens, O-alkyl, O-acyl, O-aryl, CN, NH and N ; T&prime; is selected from the group comprising H and halogens and where more than one T&prime; is present they may be the same or different; T&Prime; is selected from the group comprising H and halogens, and W is selected from the group comprising H, a phosphate group and a pharmacologically acceptable salt, derivative or prodrug thereof shows potent anti-viral activity against, for example, varicella zoster virus and cytomegalovirus.

Anti-viral pyrimidine nucleoside analogues

Growing community of inventors

Oxfordshire, United Kingdom

Christopher John Yarnold